Recently, PD-L1/PD-1 immune checkpoint inhibitors were approved by the U.S. Food and Drug Administration (FDA) to treat recurrent and metastatic HNSCC, regardless of HPV or p16 status [49]. Here, CDKN2A is linked to head and neck squamous cell carcinoma.